What is ORASCOVERYTM? Oral Drug Discovery Platform Technology

Many anticancer drugs are substrates of P-glycoprotein, and when orally administered, they will be pumped back into the GI tract, thereby limiting the drugs to intravenous administration.

The novel P-gp inhibitor encequidar (formerly known as HM30181A) forms the cornerstone of Hanmi’s Orascovery technology as an oral absorption enhancer. Encequidar enables the oral absorption of a wide range of effective anticancer drugs, which can currently only be given intravenously, due to poor oral absorption. This feature localizes P-gp inhibitory activity in the GI tract, improving the absorption of chemotherapy agents

ORASCOVERY technology has been licensed out to Athenex, and has already been applied to various anticancer drugs such as paclitaxel, docetaxel, irinotecan, topotecan and eribulin. We believe it will help to develop new oral formulations with more useful indications.
(For more information: https://www.athenex.com/pipeline/orascovery-platform)